174 related articles for article (PubMed ID: 23109108)
1. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin.
Akaike N; Shin MC; Wakita M; Torii Y; Harakawa T; Ginnaga A; Kato K; Kaji R; Kozaki S
J Physiol; 2013 Feb; 591(4):1031-43. PubMed ID: 23109108
[TBL] [Abstract][Full Text] [Related]
2. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats.
Torii Y; Akaike N; Harakawa T; Kato K; Sugimoto N; Goto Y; Nakahira S; Kohda T; Kozaki S; Kaji R; Ginnaga A
J Pharmacol Sci; 2011; 117(4):275-85. PubMed ID: 22123262
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.
Torii Y; Kiyota N; Sugimoto N; Mori Y; Goto Y; Harakawa T; Nakahira S; Kaji R; Kozaki S; Ginnaga A
Toxicon; 2011 Jan; 57(1):93-9. PubMed ID: 21029745
[TBL] [Abstract][Full Text] [Related]
4. Neurotoxin A2NTX blocks fast inhibitory and excitatory transmitter release from presynaptic terminals.
Yamaga T; Aou S; Shin MC; Wakita M; Akaike N
J Pharmacol Sci; 2012; 118(1):75-81. PubMed ID: 22198005
[TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy and toxicity between botulinum toxin subtypes A1 and A2 in cynomolgus macaques.
Torii Y; Sasaki M; Shin MC; Akaike N; Kaji R
Toxicon; 2018 Oct; 153():114-119. PubMed ID: 30193802
[TBL] [Abstract][Full Text] [Related]
6. Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses.
Akaike N; Ito Y; Shin MC; Nonaka K; Torii Y; Harakawa T; Ginnaga A; Kozaki S; Kaji R
Toxicon; 2010 Dec; 56(8):1315-26. PubMed ID: 20674584
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies.
Torii Y; Goto Y; Nakahira S; Kozaki S; Ginnaga A
Toxicon; 2014 Jan; 77():114-20. PubMed ID: 24269688
[TBL] [Abstract][Full Text] [Related]
8. Contralateral Botulinum Toxin Improved Functional Recovery after Tibial Nerve Repair in Rats.
Lima W; Salles AG; Faria JCM; Nepomuceno AC; Salomone R; Krunn P; Gemperli R
Plast Reconstr Surg; 2018 Dec; 142(6):1511-1519. PubMed ID: 30188467
[TBL] [Abstract][Full Text] [Related]
9. Repeated stimuli for axonal growth causes motoneuron death in adult rats: the effect of botulinum toxin followed by partial denervation.
White CM; Greensmith L; Vrbová G
Neuroscience; 2000; 95(4):1101-9. PubMed ID: 10682717
[TBL] [Abstract][Full Text] [Related]
10. Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A.
Marchand-Pauvert V; Aymard C; Giboin LS; Dominici F; Rossi A; Mazzocchio R
J Physiol; 2013 Feb; 591(4):1017-29. PubMed ID: 23045348
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats.
Torii Y; Goto Y; Nakahira S; Kozaki S; Kaji R; Ginnaga A
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):524-8. PubMed ID: 25395371
[TBL] [Abstract][Full Text] [Related]
12. Antinociceptive effects of A1 and A2 type botulinum toxins on carrageenan-induced hyperalgesia in rat.
Shin MC; Yukihira T; Ito Y; Akaike N
Toxicon; 2013 Mar; 64():12-9. PubMed ID: 23270755
[TBL] [Abstract][Full Text] [Related]
13. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
[TBL] [Abstract][Full Text] [Related]
14. Evidence for central antispastic effect of botulinum toxin type A.
Matak I
Br J Pharmacol; 2020 Jan; 177(1):65-76. PubMed ID: 31444910
[TBL] [Abstract][Full Text] [Related]
15. Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins.
Takeuchi T; Okuno T; Miyashiro A; Kohda T; Miyamoto R; Izumi Y; Kozaki S; Kaji R
Toxins (Basel); 2021 Nov; 13(11):. PubMed ID: 34822610
[TBL] [Abstract][Full Text] [Related]
16. Clinical differences between A1 and A2 botulinum toxin subtypes.
Kaji R
Toxicon; 2015 Dec; 107(Pt A):85-8. PubMed ID: 26394198
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons.
Shin MC; Wakita M; Xie DJ; Yamaga T; Iwata S; Torii Y; Harakawa T; Ginnaga A; Kozaki S; Akaike N
J Pharmacol Sci; 2012; 118(1):33-42. PubMed ID: 22156364
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from Gastrocnemius Muscle.
Caron G; Marqueste T; Decherchi P
PLoS One; 2015; 10(10):e0140439. PubMed ID: 26485650
[TBL] [Abstract][Full Text] [Related]
19. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons.
Restani L; Giribaldi F; Manich M; Bercsenyi K; Menendez G; Rossetto O; Caleo M; Schiavo G
PLoS Pathog; 2012 Dec; 8(12):e1003087. PubMed ID: 23300443
[TBL] [Abstract][Full Text] [Related]
20. Minocycline, a microglial inhibitor, blocks spinal CCL2-induced heat hyperalgesia and augmentation of glutamatergic transmission in substantia gelatinosa neurons.
Huang CY; Chen YL; Li AH; Lu JC; Wang HL
J Neuroinflammation; 2014 Jan; 11():7. PubMed ID: 24405660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
